Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors

Author(s): Zhili Liu, Jing Zhang and Ao Zhang

Volume 15, Issue 6, 2009

Page: [682 - 718] Pages: 37

DOI: 10.2174/138161209787315639

Price: $65

Abstract

More and more evidences are still accumulating rapidly on the G-protein-coupled-receptors (GPCRs) dimerization/ oligomerization. Such common feature of GPCRs has called extensive attention to both pharmacologists and medicinal chemists for illustration of the pharmacological functions and therapeutic utilities of such receptor complex. Although there is still no clear explanation for the receptor dimerization/oligomerization, a large number of multivalent ligands (MLs) have been designed to target the receptor-dimers/oligomers. Such MLs have gained much acceptance in exploring the receptor complex of dopaminergic, adrenergic, serotoninergic, and opioidic receptor systems, due to the relatively broader experience in recognizing the receptor-dimerization. More and more MLs have also been designed to face GPCRrelated very complex neurodegenerative diseases, such as Parkinsons disease (PD), Alzheimers disease (AD) and schizophrenia, which are not effectively treated by traditional highly selective drugs. Herein, some of the most recent developments in this field, as well as some typical examples of MLs, are highlighted, with a particular focus on GPCRs.

Keywords: Multivalent ligand, G-protein-coupled receptors (GPCRs), drug design and development, heterodimerization, Parkinson's disease, Alzheimer's disease, schizophrenia, drug abuse, drug target


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy